MannKind (MNKD) investor relations material

Key catalysts and recent developments

• Pediatric approval for Afrezza expands its use to patients six and older, with early adoption showing strong enthusiasm among academic centers and encouraging refill rates.

• FUROSCIX ReadyFlow autoinjector launch is generating high physician interest, with order rates surpassing previous device versions and expanding into new prescriber groups.

• Phase I-B data for the 201 program in IPF was positive, prompting a redesigned phase II trial with results expected in the first half of 2028.

Commercial execution and market expansion

• Focus for the next 12–24 months is on driving net sales for Afrezza and FUROSCIX, and executing on development milestones for the 201 program.

• ReadyFlow is expected to broaden the FUROSCIX market by reducing device complexity, attracting both existing and new prescribers in cardiology and nephrology.

• Efforts are underway to embed ReadyFlow in hospital discharge protocols, with real-world evidence studies planned to support adoption in the IDN space.

Market access and reimbursement

• Pediatric Afrezza launch is supported by a bridge program ensuring initial access for $35, with most patients transitioning to paid coverage after initial scripts.

• Reimbursement dynamics for pediatric use mirror the adult market, but broader payer engagement is ongoing due to the expanded product portfolio.